Drugs / DS-1040b
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02647307 | Feb → Jun 2016 | — | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 1 | NCT02560688 | Dec 2015 → Mar 2016 | — | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 1 | NCT02071004 | Jan → Feb 2014 | ischemic stroke | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02923115 | Jun 2016 → Aug 2019 | pulmonary embolism, thrombotic disease | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 1/2 | NCT02586233 | Sep 2015 → Aug 2019 | ischemic stroke, thrombotic disease | Daiichi Sankyo | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03198715 | Jul 2017 → Jan 2020 | ischemic stroke | Daiichi Sankyo | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DS-1040b | “Participants receive DS-1040b 0.6 mg by intravenous infusion over six hours” NCT03198715 ↗ |
| Action | Inhibit | “inhibitor of activated thrombin-activatable fibrinolysis inhibitor” PMID 32106339 ↗ Feb 2020 |
| Modality | Small molecule | “novel low-molecular-weight inhibitor” PMID 32106339 ↗ Feb 2020 |
| Route | Intravenous | “IV of 6 mg given once over 30 minutes” NCT02071004 ↗ |